Qure.ai, a leader in healthcare Artificial Intelligence (AI), will present its AI-powered lung cancer continuum at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, from May 31 to June 4, 2024.

This suite of AI solutions aims to enhance the entire lung cancer care process, aiding clinicians and advancing developments in the pharmaceutical and medical device industries.

"Lung cancer is the top cause of cancer-related deaths worldwide, with about 75% of patients diagnosed at an advanced stage.

Warier emphasizes AI's crucial role in early lung cancer detection, noting its ability to identify small pulmonary nodules during routine healthcare imaging procedures, beyond existing screening programs.

This capability facilitates earlier diagnosis and referral for treatment, addressing the issue of low lung cancer screening appointment rates.

The Qure.ai lung cancer continuum provides regulatory-cleared tools designed to improve patient care through:

AI-driven identification of missed lung nodules from chest X-rays to support early diagnosis.
AI-based measurement of lung nodules via CT scans, tracking volumetric growth for monitoring disease progression.

AI tools for managing lung cancer cases with multi-modality reporting, collaboration, and prioritization features.

AI monitoring of drug efficacy and disease progression in clinical trials and cancer care research.

Qure.ai has a robust track record with AI deployments in over 2700 sites across more than 90 countries. The company is trusted by global institutions and collaborates with partners such as AstraZeneca, the UK's National Health Service (NHS) hospitals, and major teleradiology companies in the UK and US. Qure.ai is headquartered in Mumbai, with offices in New York and London.





Source: qure.ai

Report Abuse